Science Corporation implants its vision-restoring chip in its first Stargardt disease patient

Max Hodak, co-founder and former president of Neuralink, revealed details about his new company's advancements at TechCrunch Disrupt. His venture has successfully implanted its vision-restoring chip, named PRIMA, into its first human patient suffering from Stargardt disease. This significant step represents a crucial milestone on the company's trajectory toward developing a novel brain-computer interface (BCI). The move is noteworthy as it marks a progression from theoretical discussions to practical, human application in the field of neural technology and offers potential hope for individuals with debilitating vision impairments like Stargardt disease. The implant is part of a broader strategy to interface the human brain directly with external computing systems, an area pioneered by Hodak in his previous role. This development is important for the scientific and medical communities, potentially paving the way for future therapeutic applications and a deeper understanding of human-computer interaction.